Answers are grounded in this paper and cite their sources.
Retrospective study shows brain-to-liver FDG uptake ratio predicts survival in multiple myeloma, indicating its prognostic relevance.
Purpose [¹⁸F]FDG PET/CT has been widely used in oncology for diagnosis and treatment monitoring. Reduced cerebral [¹⁸F]FDG uptake has been observed in patients with disseminated malignancies, potentially associated with the Warburg effect and elevated lactate levels. This study investigated the prognostic relevance of the brain-to-liver [¹⁸F]FDG uptake ratio (BLR) in MM patients who underwent PET/CT at diagnosis. Methods BLR was calculated as the ratio between the mean standardized uptake value (SUV) of the whole brain and that of the liver. A total of 72 patients were retrospectively included in the study (58% male; median age 65 years (IQR55;70); 67% were classified as ISS stage III). Results BLR, as a continuous variable, showed a statistically significant difference between groups according to sex ( p = 0.004), overweight status ( p = 0.005), and ISS stage ( p = 0.03), and was negatively correlated with β₂-microglobulin ( r = − 0.42, p < 0.001). With a median follow-up of 23 months (IQR 8; 65), 74% patients had died from MM-related causes. Patients with BLR > 2.7 demonstrated superior 60-month overall survival (52%vs.10%, p = 0.002) and progression-free survival (19%vs.3%, p = 0.003), respectively. Multivariate Cox regression confirmed BLR (HR 1.86 95%CI: 1.03–3.33, p = 0.038 (OS); HR 1.93 95%CI: 1.13–3.29, p = 0.016 (PFS))as an independent factor and the use of autologous hematopoietic cell transplantation (HCT) as consolidation for both OS and PFS. In addition, ISS stage III was also a prognostic factor for OS. Conclusion Higher brain-to-liver [¹⁸F]FDG uptake ratio (> 2.7) at diagnosis predicts better clinical outcomes in multiple myeloma. BLR is significantly associated with established clinical markers of tumor burden in multiple myeloma. These findings suggest that BLR is a feasible and reproducible metric with potential prognostic value in multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: